Cancer treatments – here’s your guide to R&D and sales potentials
Do you want to assess the future of cancer-treating medicines? Visiongain’s new report gives you revenue predictions for that industry from 2014, helping you stay ahead. You find financial data, R&D trends, opportunities and outlooks for therapy.
In that analysis you see forecasted sales to 2024 at overall world market, submarket, product and national level. You also assess emerging trends, technologies, and expected therapies.
Events shaping that pharmaceuticals industry – why cancer remains healthcare’s top priority
Discover, then, what the future holds for anti-cancer products. And find how patients can benefit. Read on to explore that industry and see what its future market could be worth.
Forecasts to 2024 and other analyses show you sales prospects
Besides revenue forecasting to 2024, you find historical data, growth rates and market shares. You assess quantitative and qualitative analyses, business news, outlooks and developments (R&D). You also gain 128 tables, 145 charts and four interviews.
Is finding data for cancer treatment a challenge? Finding information there just got easier. Our work lets you investigate the most promising and lucrative parts of applied oncology. Avoid missing out. Instead you can stay ahead in knowledge and benefit your influence.
Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses and decisions for medicines including biological drugs (biologics).
And the following sections show how you gain from our new investigation.
Outlooks for that world market and its submarkets – where does the money lie?
Along with prediction of overall world market value to 2024, our report shows you individual revenue forecasting of four submarkets at world level:
• Immunotherapy
• Chemotherapies
• Targeted treatments
• Hormone-based agents.
Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your company to develop. Assess leading brands too.
Forecasts for 25 leading drugs and 23 emerging therapies – see potentials
How will leading drugs perform to 2024 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:
• Avastin
• Herceptin
• Rituxan/MabThera
• Glivec/Gleevec
• Revlimid
• Alimta
• Velcade.
You also discover individual selling potentials of 23 rising and emerging therapies, including these:
• Beleodaq
• Zykadia
• Cyramza
• Imbruvica
• Gazyva.
There you discover how high sales can go, to 2024, finding drugs and years with highest predicted growth and revenues. You see what’s happening, then, understanding trends, competition, challenges and opportunities.
In our study you also find geographical revenue predictions.
Leading national markets – where lie highest revenues and growth?
Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.
In developed and developing countries, opportunities for pharma companies will occur from 2014. See where and how.
Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (the EU5 group)
• Brazil, Russia, India and China (BRIC nations).
There you find potential. Our analyses show sales growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2014 to 2024 will change medical prescribing and the commercial landscape. See what’s possible for R&D.
Research and development – assess innovation, trends and possibilities
What’s happening in oncological R&D? You find trends for treating these cancers:
• Bladder
• Brain
• Breast
• Cervix
• Gut
• Kidney
• Leukaemia
• Liver
• Lung.
Our study also discusses products in development for these cancers:
• Lymphoma
• Multiple myeloma
• Ovary
• Pancreas
• Prostate
• Sarcoma and skin
• Stomach
• Other related diseases and neoplasms, including solid tumours (tumors).
R&D in oncology holds strength, variety and promise. You assess innovations for those disorders, hearing about developments and finding their significance. Discover progress.
For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also see what shapes that market from 2014.
Forces affecting the industry and market for anti-cancer medicines
Our report discusses issues and events affecting that industry and market from 2014, including these:
• Epidemiology – incidence, prevalence, mortality and survival
• Resistance to treatment, tumour (tumour) heterogeneity, dedifferentiation, invasiveness and metastasis
• Personalised medicine, targeted therapy, in vivo diagnostics (IVD) and theranostics
• Cost-effectiveness, pricing and reimbursement
• Payers and healthcare policy.
The study also discusses other aspects of cancer treatment, including these:
• Monoclonal antibodies (mAbs), cancer vaccines and others, inc. blockbusters
• Efficacy, cytotoxicity and improving treatment effectiveness and safety
• Biosimilars (follow-on-protein products) and generics (generic drugs)
• Genomics and genome screening
• Biomarkers and diagnostic tests.
That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that business. You also analyse the anti-cancer drug industry’s strengths, weaknesses, opportunities and threats (SWOT).
Discover what the future holds.
Leading companies in cancer treatment and 2018 market value
From 2014, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $122.3bn in 2018, expanding further to 2024. What’s possible there?
Our analysis shows you what technologies, products and organisations hold greatest potential. They cover these leading companies, among others:
• Roche
• Novartis
• Celgene
• Eli Lilly
• AstraZeneca
• Bristol-Myers Squibb
• Merck & Co.
Prospects for sales and R&D in oncology are strong, and from 2014 there will arise many opportunities. See where. Our report shows you the possibilities, helping you stay ahead.
Eight ways Anti-Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2014-2024 helps you
In particular, our new analysis gives the following knowledge to help your work:
• World anti-cancer drugs market revenue to 2024 – discover the sales potential of that industry
• Four product classes’ revenues to 2024 – investigate categories at world level, finding the most lucrative and promising groups
• 25 leading drugs and 23 emerging and rising therapies’ revenues to 2024 – find sales predictions for top treatments, seeing how they can compete and succeed
• 11 national markets in the Americas, Europe and Asia – forecasts to 2024 – discover the best countries and regions for commercial expansion
• Activities of established, rising and emerging companies – hear about firms’ products, capabilities, advances and outlooks
• Research and development (R&D) – investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities
• Interviews with four organisations – discover other experts’ views, gaining feel for that industry
• Analysis of what stimulates and restrains the cancer treatments industry and market – assess challenges and strengths, helping you find advantages and succeed.
Data there found nowhere else, benefiting your influence in pharma biotechnology
Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where business prospects are most rewarding.
With that investigation you’re less likely to fall behind in data or miss opportunity. Discover there, by your choice, how to help your information searches, analyses and decisions. Also find how you could save time and gain in authority for technological and commercial insight.
Trying our report now lets you discover biopharma opportunities and predictions
Our new report is for everyone analysing cancer-treating drugs. There you find trends, opportunities and sales predictions. Avoid missing out – please get that study here now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. The World Anti-Cancer Drug Market, 2014-2024
3.1 Global Anti-Cancer Drugs Market Forecast, 2014-2024
3.2 The Domination of Immunotherapies in 2013
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2014-2024 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2014-2024
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2014-2024 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2014-2024
4. Leading National Markets, 2014-2024
4.1 Anti-Cancer Drugs – Leading Markets, 2013
4.2 The US Anti-Cancer Drugs Market, 2014-2024 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2013
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Regulatory Effect on the US Market
4.3 The Japanese Anti-Cancer Drug Market, 2014-2024 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2014-2024 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2014-2024 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2014-2024 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2014-2024 - Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2014-2024 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2014-2024 – Can it Fulfil its Potential?
5. The Top 25 Anti-Cancer Drugs, 2014-2024
5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2010-2013 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2010-2013 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2010-2013 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2010-2013
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2010-2013 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2010-2013
5.6.2 Alimta Revenue Forecast– Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2010-2013
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/ Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2010-2013
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co) – The Rise of Preventions
5.9.1 Gardasil Revenue, 2010-2013
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2010-2013 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2010-2013 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2010-2013 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2010-2013 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2010-2013
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving on Up
5.15.1 Tasigna Revenue, 2010-2013
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16 Sutent (Pfizer)
5.16.1 Sutent Revenue, 2010-2013
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2010-2013 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start to the Decade
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2010-2013 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2010-2013
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2013
5.20.2 Yervoy Revenue Forecast – Will it Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2010-2013
5.21.2 Vidaza Revenue Forecast – Generic Impact
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2010-2013
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2010-2013
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2010-2013
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2012-2013
5.25.2 Abraxane Revenue Forecast
6. Drugs Approved in 2013-2014: Potential Future Blockbusters
6.1 Approved Treatments in 2014
6.1.1 Beleodaq (Topotarget/Spectrum Pharmaceuticals)
6.1.1.1 Market Potential
6.1.2 Zykadia (Novartis) – The Rise of Kinase Inhibitors
6.1.2.1 Market Potential
6.1.3 Cyramza (Eli Lilly) – A Breakthrough for Gastric Cancer?
6.1.3.1 Market Potential
6.2 Approved Treatments in 2013
6.2.1 Imbruvica (Pharmacyclics)
6.2.1.1 Market Potential
6.2.2 Gazyva (Roche) – The First Breakthrough Therapy
6.2.2.1 Market Potential
6.2.3 Gilotrif (Boehringer Ingelheim)
6.2.3.1 Market Potential
6.2.4 Mekinist (GSK) – A First-in-Class Treatment for Melanoma
6.2.4.1 Market Potential
6.2.5 Tafinlar (GSK) – A Partner for Mekinist
6.2.5.1 Market Potential
6.2.6 Kadycla (Roche) – A Future Star
6.2.6.1 Market Potential – A Replacement for Herceptin?
6.2.7 Pomalyst (Celgene)
6.2.7.1 Market Potential
6.3 Drugs Approved in 2012 – How They’re Doing Now
6.3.1 Afinitor (Novartis) – Already a Blockbuster
6.3.1.1 Market Potential
6.3.2 Bosulif (Pfizer) – How Will it Perform?
6.3.2.1 Market Potential
6.3.3 Cometriq (Exelixis)
6.3.3.1 Market Potential
6.3.4 Erivedge (Roche) – Will It Become a Blockbuster?
6.3.4.1 Market Potential
6.3.5 Iclusig (Ariad)
6.3.5.1 Market Potential – Wider Uses?
6.3.6 Inlyta (Pfizer) – A Good Second-Line Option?
6.3.6.1 Market Potential
6.3.7 Kyprolis (Amgen)
6.3.7.1 Market Potential
6.3.8 Marqibo (Talon) – Will Its Revenue Grow?
6.3.8.1 Market Potential
6.3.9 Perjeta (Roche) – Joining the HER2 Family
6.3.9.1 Market Potential
6.3.10 Stivarga (Bayer)
6.3.10.1 Market Potential
6.3.11 Synribo (Teva)
6.3.11.1 Market Potential
6.3.12 Votrient (GSK)
6.3.12.1 Market Potential
6.3.13 Xtandi (Medivation) – Quickly Becoming a Popular Choice
6.3.13.1 Market Potential
6.3.14 Zaltrap (Sanofi)
6.3.14.1 Market Potential
7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – Pressing Need to Diversify?
7.4.1Celgene’s Oncology Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing up the Ladder
7.6.1 Oncology Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck & Co. – Prominent in Vaccines
7.8.1 Oncology Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
8. R&D Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs Under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Palbociclib (Pfizer)
8.1.3 Veliparib (Abbvie)
8.1.4 NeuVax (Galena Biopharma)
8.1.5 Entinostat (Syndax)
8.2 Prostate Cancer Drugs Under Development
8.2.1 OMD-201 (Orion)
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs Under Development
8.3.1 Tecemotide (Merck Serono)
8.3.2 RG7446 (Roche)
8.3.3 Nivolumab (Bristol-Myers Squibb)
8.3.4 MEDI4736 (AstraZeneca)
8.3.5 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs Under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 TAS-102 (Taiho Pharmaceuticals)
8.4.4 HA-Irinotecan (Alchemia)
8.4.5 Aptocine (Light Sciences Oncology)
8.5 Cervical Cancer Drugs Under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs Under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs Under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec9 (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs Under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.8.4 SG2000 (Spirogen)
8.9 Bladder Cancer Drugs Under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs Under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs Under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs Under Development
8.12.1 IMA901 (Immatics)
8.12.2 ASG-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)
9. Qualitative Analysis of the Anti-Cancer Drug Market 2014-2024
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment
10. Research Interviews
10.1 Interview with Mr Thomas Felzmann, CEO, Activartis Biotech GmbH, Vienna, Austria
10.1.1 Activartis Biotech and AV0113
10.2 Interview with Professor Philip Rudland, Chair of Biochemistry at the University of Liverpool
10.2.1 Identifying Markers in Cancer Cells
10.2.2 The Importance of Protein Expression
10.2.3. The Advancement of Diagnostics
10.2.4 The Future of the Anti-Cancer Drug Market
10.3 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University
10.3.1 On His Research Interests and their Utility in Anti-Cancer Drug Development
10.3.2 On the Evaluation of New Targets for Anti-Cancer Drugs
10.3.3 On Drug Resistance and Targeted Therapies
10.3.4 On the Future of Traditional Chemotherapy
10.3.5 On Future Developments in the Anti-Cancer Field
10.4 Interview with Dr Neil Butt, Director, Antitope Ltd.
10.4.1 On Immunogenicity in Therapeutic Proteins
10.4.2 On Antitope’s Technologies to Assess and Reduce Immunogenicity
10.4.3 On an Alternative Way of Reducing Immunogenicity
10.4.4 On Biosimilars
10.4.5 On Future Developments in that Field
11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks
List of Tables
Table 1.1 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2013-2018
Table 1.2 Forecast Regional and National Anti-Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013
Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013
Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013
Table 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.2 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2012-2013
Table 3.3 Global Anti-Cancer Drugs Market by Therapeutic Area: Revenue Forecast ($bn), CAGR (%) and Market Share (%), 2013, 2018 and 2024
Table 3.4 Global Immunotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.5 Global Chemotherapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.6 Global Targeted Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 3.7 Global Hormone Therapy Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.1 Anti-Cancer Drugs Market Revenue ($bn) and Market Share (%) by Leading Country, 2013, 2018, 2024
Table 4.2 Leading National Anti-Cancer Drugs Markets: Revenue Forecast ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2014-2024
Table 4.3 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.4 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.5 EU5 Anti-Cancer Drugs Market Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.6 The BRIC Countries Anti-Cancer Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.7 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.8 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.9 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 4.10 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.1 Top 25 Anti-Cancer Drugs: Revenue ($bn) and Market Share (%), 2013
Table 5.2 Top 10 Anti-Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2013, 2018, 2024
Table 5.3 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024
Table 5.4 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024 (Contd.)
Table 5.5 Top 25 Anti-Cancer Drugs: Revenue Forecasts ($bn), 2014-2024 (Contd.)
Table 5.6 Avastin Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.7 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.8 Herceptin Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.9 Herceptin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.10 Rituxan/MabThera Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.11 Rituxan/MabThera Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.12 Glivec Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.13 Glivec Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.14 Revlimid Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.15 Revlimid Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.16 Alimta Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.17 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.18 Velcade Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.19 Velcade Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.20 Erbitux Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.21 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.22 Gardasil Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.23 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.24 Zytiga Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
Table 5.25 Zytiga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.26 Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.27 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.28 Tarceva Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.29 Tarceva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.30 Afinitor Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.31 Afinitor Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.32 Sprycel Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.33 Sprycel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.34 Tasigna Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.35 Tasigna Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.36 Sutent Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.37 Sutent: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.38 Nexavar Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.39 Nexavar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.40 Xgeva Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.41 Xgeva Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.42 Zoladex Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.43 Zoladex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.44 Yervoy Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
Table 5.45 Yervoy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.46 Vidaza Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.47 Vidaza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.48 Treanda Revenue ($bn), Annual Growth (%) and CAGR (%), 2011-2013
Table 5.49 Treanda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.50 Temodar Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.51 Temodar Revenue Forecast (%bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 5.52 Faslodex Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.53 Faslodex Revenue Forecast ($bn), Annual Growth (%) and CAGR, 2014-2024
Table 5.54 Abraxane Revenue ($bn), Annual Growth (%) and CAGR (%), 2010-2013
Table 5.55 Abraxane: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.1 Beleodaq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.2 Zykadia: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.3 Cyramza: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.4 Imbruvica: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.5 Gazyva: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.6 Gilotrif: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.7 Mekinist: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.8 Tafinlar: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.9 Kadcyla: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.10 Pomalyst: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.11 Bosulif: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.12 Cometriq: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.13 Erivedge: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.14 Iclusig: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.15 Inlyta: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.16 Kyprolis: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.17 Marqibo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.18 Perjeta: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.19 Stivarga: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.20 Synribo: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.21 Votrient: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.22 Xtandi: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 6.23 Zaltrap: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2024
Table 7.1 Anti-Cancer Drug Revenues ($bn) and Market Shares (%) of Leading Companies, 2012-2013
Table 7.2 Roche – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.3 Roche’s Anti-Cancer Drug Development Pipeline, 2013
Table 7.4 Novartis – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.5 Novartis’ Anti-Cancer Drug Pipeline, 2013
Table 7.6 Celgene – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.7 Celgene’s Anti-Cancer Drug Pipeline, 2013
Table 7.8 Eli Lilly – Anti-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2013
Table 7.9 Eli Lilly’s Anti-Cancer Drug Pipeline, 2013
Table 7.10 AstraZeneca – Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
Table 7.11 AstraZeneca’s Anti-Cancer Drug Pipeline, 2013
Table 7.12 Bristol-Myers Squibb – Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
Table 7.13 Bristol-Myers Squibb Anti-Cancer Drug Pipeline, 2013
Table 7.14 Merck – Anti-Cancer Drugs by Revenue ($bn), Percent Change and Share (%), 2013
Table 7.15 Merck’s Anti-Cancer Drug Pipeline, 2013
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
Table 8.2 Breast Cancer Drugs under Development, 2013
Table 8.3 Prostate Cancer Drugs under Development, 2013
Table 8.4 Lung Cancer Drugs under Development, 2013
Table 8.5 Colorectal Cancer Drugs under Development, 2013
Table 8.6 Cervical Cancer Drugs under Development, 2013
Table 8.7 Stomach Cancer Drugs under Development, 2013
Table 8.8 Liver Cancer Drugs under Development, 2013
Table 8.9 Ovarian Cancer Drugs under Development, 2013
Table 8.10 Bladder Cancer Drugs under Development, 2013
Table 8.11 Non-Hodgkin’s Lymphoma Drugs under Development, 2013
Table 8.12 Leukaemia Drugs under Development, 2013
Table 8.13 Kidney Cancer Drugs under Development, 2013
Table 8.14 Pancreatic Cancer Drugs under Development, 2013
Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2014
Table 9.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2014
List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years Old (millions), Annual Growth Rate (%), 2013-2024
Figure 1.2 Anti-Cancer Market Segmentation, 2014
Figure 3.1 The Global Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
Figure 3.2 Global Anti-Cancer Drugs Market: Drivers and Restraints, 2014-2024
Figure 3.3 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2013
Figure 3.4 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2018
Figure 3.5 Global Anti-Cancer Drugs Market Share (%) by Therapeutic Area, 2024
Figure 3.6 Global Immunotherapy Market: Revenue Forecast ($bn), 2014-2024
Figure 3.7 Immunotherapy Market: Drivers and Restraints, 2014-2024
Figure 3.8 Global Chemotherapy Market: Revenue Forecast ($bn), 2014-2024
Figure 3.9 Chemotherapy Market: Drivers and Restraints, 2014-2024
Figure 3.10 Global Targeted Therapy Market: Revenue Forecast ($bn), 2014-2024
Figure 3.11 Targeted Therapy Market: Drivers and Restraints, 2014-2024
Figure 3.12 Global Hormone Therapy Market: Revenue Forecast ($bn), 2014-2024
Figure 3.13 Hormone Therapy Market: Drivers and Restraints, 2014-2024
Figure 4.1 Developed National Markets: Drivers and Restraints, 2014-2024
Figure 4.2 Emerging National Markets: Drivers and Restraints, 2014-2024
Figure 4.3 Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2013
Figure 4.4 Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2018
Figure 4.5 Leading National Anti-Cancer Drugs Markets by Share of Global Market (%), 2024
Figure 4.6 The US Anti-Cancer Drugs Market Revenue Forecast ($bn), 2014-2024
Figure 4.7 The Japanese Anti-Cancer Drugs Market Revenue Forecast ($bn), 2014-2024
Figure 4.8 The EU5 Anti-Cancer Drugs Markets: Revenue Forecast ($bn), 2014-2024
Figure 4.9 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2013
Figure 4.10 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2018
Figure 4.11 The EU5 Countries: Shares of the Anti-Cancer Drugs Market (%), 2024
Figure 4.12 BRIC Countries Anti-Cancer Drugs Market Share (%), 2013
Figure 4.13 BRIC Countries Anti-Cancer Drugs Market Share (%), 2018
Figure 4.14 BRIC Countries Anti-Cancer Drug Market Share (%), 2024
Figure 4.15 Brazilian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
Figure 4.16 Russian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
Figure 4.17 Indian Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
Figure 4.18 Chinese Anti-Cancer Drugs Market: Revenue Forecast ($bn), 2014-2024
Figure 5.1 Top 10 Anti-Cancer Drugs: Market Share (%), 2013
Figure 5.2 Top 10 Anti-Cancer Drugs: Market Share (%), 2018
Figure 5.3 Top 10 Anti-Cancer Drugs: Market Share (%), 2024
Figure 5.4 Avastin Revenue ($bn), 2010-2013
Figure 5.5 Avastin Revenue Forecast ($bn), 2014-2024
Figure 5.6 Avastin: Drivers and Restraints, 2014-2024
Figure 5.7 Herceptin Revenue ($bn), 2010-2013
Figure 5.8 Herceptin Revenue Forecast ($bn), 2014-2024
Figure 5.9 Herceptin: Drivers and Restraints, 2014-2024
Figure 5.10 Rituxan/MabThera Revenue ($bn), 2010-2013
Figure 5.11 Rituxan/MabThera Revenue Forecast ($bn), 2014-2024
Figure 5.12 Rituxan/MabThera: Drivers and Restraints, 2014-2024
Figure 5.13 Glivec Revenue ($bn), 2010-2013
Figure 5.14 Glivec Revenue Forecast ($bn), 2014-2024
Figure 5.15 Glivec: Drivers and Restraints, 2014-2024
Figure 5.16 Revlimid Revenue ($bn), 2010-2013
Figure 5.17 Revlimid Revenue Forecast ($bn), 2014-2024
Figure 5.18 Revlimid: Drivers and Restraints, 2014-2024
Figure 5.19 Alimta Revenue ($bn), 2010-2013
Figure 5.20 Alimta Revenue Forecast ($bn), 2014-2024
Figure 5.21 Alimta: Drivers and Restraints, 2014-2024
Figure 5.22 Velcade Revenue ($bn), 2010-2013
Figure 5.23 Velcade Revenue Forecast ($bn), 2014-2024
Figure 5.24 Velcade: Drivers and Restraints, 2014-2024
Figure 5.25 Erbitux Revenue ($bn), 2010-2013
Figure 5.26 Erbitux Revenue Forecast ($bn), 2014-2024
Figure 5.27 Erbitux: Drivers and Restraints, 2014-2024
Figure 5.28 Gardasil Revenue ($bn), 2010-2013
Figure 5.29 Gardasil Revenue Forecast ($bn), 2014-2024
Figure 5.30 Gardasil: Drivers and Restraints, 2014-2024
Figure 5.31 Zytiga Revenue ($bn), 2011-2013
Figure 5.32 Zytiga Revenue Forecast ($bn), 2014-2024
Figure 5.33 Zytiga: Drivers and Restraints, 2014-2024
Figure 5.34 Xeloda Revenue ($bn), 2010-2013
Figure 5.35 Xeloda Revenue Forecast ($bn), 2014-2024
Figure 5.36 Xeloda: Drivers and Restraints, 2014-2024
Figure 5.37 Tarceva Revenue, 2010-2013
Figure 5.38 Tarceva: Revenue Forecast ($bn), 2014-2024
Figure 5.39 Tarceva: Drivers and Restraints, 2014-2024
Figure 5.40 Afinitor Revenue ($bn), 2010-2013
Figure 5.41 Afinitor Revenue Forecast ($bn), 2014-2024
Figure 5.42 Afinitor: Drivers and Restraints, 2014-2024
Figure 5.43 Sprycel Revenue ($bn), 2010-2013
Figure 5.44 Sprycel Revenue Forecast ($bn), 2014-2024
Figure 5.45 Sprycel: Drivers and Restraints, 2014-2024
Figure 5.46 Tasigna Revenue ($bn), 2010-2013
Figure 5.47 Tasigna Revenue Forecast ($bn), 2014-2024
Figure 5.48 Tasigna: Drivers and Restraints, 2014-2024
Figure 5.49 Sutent Revenue ($bn), 2010-2013
Figure 5.50 Sutent: Revenue Forecast ($bn), 2014-2024
Figure 5.51 Sutent: Drivers and Restraints, 2014-2024
Figure 5.52 Nexavar Revenue ($bn), 2010-2013
Figure 5.53 Nexavar: Revenue Forecast ($bn), 2014-2024
Figure 5.54 Nexavar: Drivers and Restraints, 2014-2024
Figure 5.55 Xgeva Revenue ($bn), 2010-2013
Figure 5.56 Xgeva Revenue Forecast ($bn), 2014-2024
Figure 5.57 Xgeva: Drivers and Restraints, 2014-2024
Figure 5.58 Zoladex Revenue ($bn), 2010-2013
Figure 5.59 Zoladex: Revenue Forecast ($bn), 2014-2024
Figure 5.60 Zoladex: Drivers and Restraints, 2014-2024
Figure 5.61 Yervoy Revenue ($bn), 2011-2013
Figure 5.62 Yervoy Revenue Forecast ($bn), 2014-2024
Figure 5.63 Yervoy: Drivers and Restraints, 2014-2024
Figure 5.64 Vidaza Revenue ($bn), 2011-2013
Figure 5.65 Vidaza: Revenue Forecast ($bn), 2014-2024
Figure 5.66 Vidaza: Drivers and Restraints, 2014-2024
Figure 5.67 Treanda Revenue ($bn), 2011-2013
Figure 5.68 Treanda Revenue Forecast ($bn), 2014-2024
Figure 5.69 Treanda: Drivers and Restraints, 2014-2024
Figure 5.70 Temodar Revenue ($bn), 2010-2013
Figure 5.71 Temodar Revenue Forecast ($bn), 2014-2024
Figure 5.72 Temodar: Drivers and Restraints, 2014-2024
Figure 5.73 Faslodex Revenue ($bn), 2010-2013
Figure 5.74 Faslodex Revenue Forecast ($bn), 2014-2024
Figure 5.75 Faslodex: Drivers and Restraints, 2014-2024
Figure 5.76 Abraxane Revenue ($bn), 2010-2013
Figure 5.77 Abraxane: Revenue Forecast ($bn), 2014-2024
Figure 5.78 Abraxane: Drivers and Restraints, 2014-2024
Figure 6.1 Beleodaq: Revenue Forecast ($bn), 2014-2024
Figure 6.2 Zykadia: Revenue Forecast ($bn), 2014-2024
Figure 6.3 Cyramza: Revenue Forecast ($bn), 2014-2024
Figure 6.4 Imbruvica: Revenue Forecast ($bn), 2014-2024
Figure 6.5 Gazyva: Revenue Forecast ($bn), 2014-2024
Figure 6.6 Gilotrif: Revenue Forecast ($bn), 2014-2024
Figure 6.7 Mekinist: Revenue Forecast ($bn), 2014-2024
Figure 6.8 Tafinlar: Revenue Forecast ($bn), 2014-2024
Figure 6.9 Kadcyla: Revenue Forecast ($bn), 2014-2024
Figure 6.10 Pomalyst: Revenue Forecast ($bn), 2014-2024
Figure 6.11 Bosulif: Revenue Forecast ($bn), 2014-2024
Figure 6.12 Cometriq: Revenue Forecast ($bn), 2014-2024
Figure 6.13 Erivedge: Revenue Forecast ($bn), 2014-2024
Figure 6.14 Iclusig: Revenue Forecast ($bn), 2014-2024
Figure 6.15 Inlyta: Revenue Forecast ($bn), 2014-2024
Figure 6.16 Kyprolis: Revenue Forecast ($bn), 2014-2024
Figure 6.17 Marqibo: Revenue Forecast ($bn), 2014-2024
Figure 6.18 Perjeta: Revenue Forecast ($bn), 2014-2024
Figure 6.19 Stivarga: Revenue Forecast ($bn), 2014-2024
Figure 6.20 Synribo: Revenue Forecast ($bn), 2014-2024
Figure 6.21 Votrient: Revenue Forecast ($bn), 2014-2024
Figure 6.22 Xtandi: Revenue Forecast ($bn), 2014-2024
Figure 6.23 Zaltrap: Revenue Forecast ($bn), 2014-2024
Figure 7.1 Anti-Cancer Drugs Market Share (%) by Leading Company, 2012
Figure 7.2 Anti-Cancer Drugs Market Share (%) by Leading Company, 2013
Figure 7.3 Roche’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 7.4 Novartis’ Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 7.5 Celgene’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 7.6 Eli Lilly’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 7.7 AstraZeneca’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 7.8 Bristol-Myers Squibb’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 7.9 Merck’s Top Selling Anti-Cancer Drugs by Share of Company Revenue (%), 2013
Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012
Figure 12.1 Top 25 Anti-Cancer Drugs: Revenues ($bn), 2013
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
